araag2/HINT huggingface dataset:
Clinical trial NCT02257619 (phase 2, status: terminated)
Conditions: nsclc (non-small cell lung carcinoma)
ICD codes: D02.20, D02.21, D02.22
Drugs: itacitinib, docetaxel
SMILES: FC1=C(N=CC=C1C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1)C(F)(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    sponsor decision to not initiate part 2 due to slow enrollment and competing trials.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of NSCLC that is Stage IIIb, IV,
             or recurrent.

          2. Received only 1 prior systemic chemotherapy regimen for Stage IIIb, IV, or recurrent
             disease not including neoadjuvant and/or adjuvant therapy. (NOTE: Exceptions may be
             allowed based on prior treatment regimens and tumor types in agreement with protocol
             requirements.)

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

          4. Life expectancy of ≥12 weeks.

        Exclusion Criteria:

          1. Received prior treatment with docetaxel.

          2. Known active central nervous system (CNS) metastases. Subjects with CNS metastases who
             have completed a course of therapy would be eligible for the study provided they are
             clinically stable for at least 1 month prior to study entry, defined as:

               1. No evidence of new or enlarging CNS metastasis or new neurological symptoms
                  attributable to CNS metastases.

               2. Subjects who are receiving concomitant corticosteroids must be on a stable or
                  decreasing dose for at least 4 weeks prior to first dose of study treatment and
                  off all anticonvulsants for at least 4 weeks prior to study entry.

          3. Peripheral neuropathy ≥ Grade 3.

          4. Current or previous other malignancy within 2 years of study entry, except cured basal
             or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial
             neoplasm, carcinoma in situ of the cervix, or other noninvasive malignancy.

          5. Significant, concurrent, uncontrolled medical condition including but not limited to,
             renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac,
             neurological, cerebral, or psychiatric disease.

          6. Unwilling to be transfused with blood components.
Clinical trial NCT02258529 (phase 2, status: terminated)
Conditions: follicular lymphoma, small lymphocytic lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: idelalisib
SMILES: [H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Histologically confirmed diagnosis of B-cell lymphoma

          -  No previous systemic treatment for lymphoma

          -  Subject demonstrates need for treatment for lymphoma

          -  Ann-Arbor Stage 2 (noncontiguous), 3, or 4 disease

          -  Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy

          -  Adequate performance status

          -  Required baseline laboratory data within protocol-specified parameters

        Key Exclusion Criteria:

          -  Known history of transformed lymphoma or diffuse large cell lymphoid malignancy

          -  Known history of, or clinically apparent, central nervous system (CNS) lymphoma or
             leptomeningeal lymphoma

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
             enrollment

          -  Known history of drug-induced liver injury, chronic active hepatitis B (HBV), chronic
             active hepatitis C (HCV), alcoholic liver disease, non-alcoholic steatohepatitis,
             cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing
             extrahepatic obstruction caused by cholelithiasis

          -  Ongoing inflammatory bowel disease

          -  Known human immunodeficiency virus (HIV) infection

          -  History of prior allogeneic bone marrow progenitor cell or solid organ transplantation

          -  Ongoing immunosuppressive therapy, including systemic corticosteroids (> 10 mg
             prednisone or equivalent/day) with the exception of the use of topical, enteric, or
             inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for
             autoimmune anemia and/or thrombocytopenia

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02260193 (phase 2, status: completed)
Conditions: anemia, end stage renal disease
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, N18.6, I12.0, I13.11, I13.2
Drugs: akb-6548, akb-6548, akb-6548
SMILES: OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  18 to 79 years inclusive

          -  Chronic Kidney Disease (CKD) Stage 5 on chronic hemodialysis for at least 3 months

          -  Anemia secondary to CKD treated with erythropoiesis stimulating agent and intravenous
             iron

        Key Exclusion Criteria:

          -  BMI >44.0 kg/m2

          -  Transfusion within 8 weeks prior to Screening

          -  ALT or total bilirubin >1.25x ULN

          -  Uncontrolled hypertension

          -  Class III or IV congestive heart failure

          -  Myocardial infarction, acute coronary syndrome, stroke or transient ischemic attack
             within 6 months prior to Screening
Clinical trial NCT02262078 (phase 2, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: sodium nitrite inhalation solution
SMILES: ON=O
Eligibility criteria:

        Inclusion Criteria:

          -  Heart Failure with preserved Ejection Fraction (HFpEF) is defined by clinical symptoms
             of dyspnea and fatigue

          -  Normal left ventricular ejection fraction (>/=50%)

          -  And elevated Left Ventricular (LV) filling pressure at cardiac catheterization
             (defined as resting Pulmonary Capillary Wedge Pressure (PCWP)>15 mmHg and/or PCWP
             >/=25 mmHg during exercise).

        Exclusion Criteria:

          -  Systolic Blood Pressure <120 mmHg (during catheterization)

          -  Prior nitrate therapy (within previous 2 weeks)

          -  Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency

          -  Other "non-HFpEF" specific causes of heart failure such as significant valvular
             disease (>moderate left-sided regurgitation, >mild stenosis)

          -  Severe pulmonary disease

          -  Unstable coronary disease or coronary spasm

          -  Primary renal or hepatic disease (end stage renal failure/on dialysis or clinical
             diagnosis of hepatitis or hepatic cirrhosis)

          -  Constrictive pericarditis, or infiltrative, restrictive, or hypertrophic
             cardiomyopathies

          -  Pregnant
Clinical trial NCT02262728 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: simeprevir, daclatasvir, sofosbuvir
SMILES: [H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Documented chronic Hepatitis C virus (HCV) infection: diagnosis of HCV more than (>) 6
             months before the Screening visit, either by detectable HCV ribonucleic acid (RNA), a
             HCV positive antibody or the presence of histological changes consistent with chronic
             hepatitis

          -  HCV genotype 1 or 4 infection and HCV RNA plasma level >10,000 international unit per
             milliliter (IU/mL) (both determined at screening)

          -  Presence of cirrhosis, which is defined as a FibroScan with a result of >14.5
             kilopascals (kPa) at Screening

          -  HCV treatment-naive participants: participant has not received treatment with any
             approved or investigational drug for the treatment of HCV infection and HCV
             treatment-experienced participants: participant has had at least 1 documented previous
             course of a non-direct-acting antiviral agent (DAA), interferon (IFN)-based HCV
             therapy (with or without Ribavirin [RBV]). Last dose in this previous course should
             have occurred at least 2 months prior to Screening

          -  Decompensated liver disease: Panel 1: Child Pugh A (mild hepatic impairment) with
             evidence of portal hypertension [confirmed by the presence of esophageal varices on
             gastroscopy or hepatic venous pressure gradient (HVPG) greater than or equal to (>=)
             10 millimeter of mercury (mm Hg)], Panel 2: Child-Pugh B (moderate hepatic impairment)
             7 to 9 (extremes included)

        Exclusion Criteria:

          -  Co-infection with any HCV genotype

          -  Co-infection with human immunodeficiency virus (HIV)-1 or -2 (positive HIV-1 or HIV-2
             antibodies test at Screening)

          -  Co-infection with hepatitis B virus (hepatitis B surface antigen [HBsAg] positive)

          -  Any evidence of liver disease of non-HCV etiology. This includes, but is not limited
             to, acute hepatitis A infection, drug- or alcohol-related liver disease, autoimmune
             hepatitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency,
             non-alcoholic steatohepatitis, primary biliary cirrhosis, or any other non-HCV liver
             disease considered clinically significant by the Investigator

          -  Use of any disallowed therapies before the planned first dose of study drugs
Clinical trial NCT02265744 (phase 2, status: completed)
Conditions: lupus
ICD codes: D68.62, L93.0, L93.1, L93.2, M32.9, M32.0, M32.11
Drugs: bms-931699, placebo matching bms-931699
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male or female aged between 18 to 70 (included)

          -  Diagnosed with active systemic lupus erythematosus by a doctor

          -  Disease must be in patient's joints or on the skin at a minimum

          -  Taking other medications is allowed but some are excluded

        Exclusion Criteria:

          -  Diagnosed with active lupus nephritis, multiple sclerosis or rheumatoid arthritis

          -  Diagnosed with active tuberculosis or an ongoing infection with a bacteria or a virus
Clinical trial NCT02265796 (phase 2, status: completed)
Conditions: angina
ICD codes: I20.0, I23.7, I20.9, I20.1, I20.8, I25.10, I25.810
Drugs: ranolazine, sugar pill
SMILES: COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1, OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients >= 18 years of age referred for cardiac catheterization for evaluation
             of cardiac symptoms ( angina, fatigue, or shortness of breath)

          -  At least 1 indeterminate stenosis (20-80%),

          -  Fractional flow reserve (FFR) <=0.8 and PCI deferred

        Exclusion Criteria:

          -  Coronary revascularization (percutaneous coronary intervention or coronary artery
             bypass grafting) during the index procedure or anticipated within the next month

          -  acute coronary syndrome or cardiogenic shock

          -  QTc > 500 milliseconds

          -  use of strong inhibitors of CTP3A (i.e. ketoconazole, itraconazole,
             clarithromycin,nefazodone, nelfinavir, ritonavir, indinavir and saquinavir)

          -  use of inducers of CYP3A (i.e. rifampin, rifabutin, rifapentine, phenobarbital,
             phenytoin, carbamazepine, and St. John's wort)

          -  liver cirrhosis

          -  sever renal insufficiency (i.e. creatinine clearance < 30mL/min/1.73 m2)
Clinical trial NCT02267525 (phase 2, status: completed)
Conditions: gastroparesis
ICD codes: K31.84
Drugs: velusetrag, placebo
SMILES: CC(C)N1C(=O)C(=CC2=CC=CC=C12)C(=O)N[C@@H]1C[C@@H]2CC[C@H](C1)N2C[C@@H](O)CN(C)S(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Symptoms of gastroparesis (eg, nausea, early satiety, fullness, bloating, upper
             abdominal pain, retching or vomiting) for at least 3 months prior to Screening

          -  Composite score ≥2and <5 on nausea, bloating, feeling excessively full after meals,
             and not able to finish a normal-sized meal items (on the GCSI-2W) at Screening

          -  Delayed gastric emptying by either GES (gastric emptying scintigraphy) or GEBT(gastric
             emptying breath test)

          -  Upper gastrointestinal obstruction ruled out by endoscopy or other imaging (eg,
             computed tomography) after the onset of gastroparesis symptoms

          -  Willing to abstain from prohibited medications, including but not limited to,
             anticholinergics, acetylcholinesterase antagonists, or promotility medications (eg,
             metoclopramide, domperidone, prucalopride, erythromycin) for: 24 hours prior to
             gastric emptying test during Screening, if applicable; 24 hours prior to start of the
             Baseline period; and during the Baseline Period

          -  GCSI-24H 7-day mean composite score ≥2.5 and <5 at Day 1

        Exclusion Criteria:

          -  If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level >11%

          -  Prior history of gastric surgery, including but not limited to gastrectomy, gastric
             bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication, which has
             manipulated the natural anatomy of the stomach

          -  History of intrapyloric botulinum toxin injection within 3 months of Screening or
             currently has functioning implantable electric stimulator

          -  History of alcohol or drug abuse or dependence within the last year prior to Screening
Clinical trial NCT02268006 (phase 2, status: unknown status)
Conditions: rectal carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Biopsy-proven newly diagnosed primary rectal adenocarcinoma

          -  Locally advanced tumor fulfilling at least one of the following criteria on pelvic
             MRI:

               -  T ≥ 3 or

               -  N ≥ 1

               -  Positive mesorectal fascia (MRF), i.e. tumor or lymph node one mm or less from
                  the mesorectal fascia

               -  Tumor located od 0 - 15 cm above anocutaneous junction or below peritoneum

          -  Age 18 years and more

          -  Signed informed consent

          -  WHO Performance Status 0-2

          -  Patients is considered to be mentally and physically ft for chemotherapy as judged by
             oncologist

          -  Adequate hematological, hepatic and renal function (WBC ≥ 3.0 x 109/L, neu ≥ 1.5 x
             109/L, platelet count ≥ 100 x 109/L, renal clearance ≥ 50 ml/min, bilirubin ≤ 3x
             normal value, aspartate transaminase/alanine transaminase (AST/ALT) ≤ 2,5x normal
             value)

        Exclusion Criteria:

          -  T4 inoperable tumor - extensive growth into cranial part of the sacrum (above S3) or
             the lumbosacral nerve roots

          -  Metastatic or recurrent rectal cancer

          -  Other co-existing malignancy or malignancy within the past 5 years, with the exception
             of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the
             skin

          -  Chronic bowel inflammatory disease

          -  Pregnant or lactating patient

          -  Significant heart disease (uncontrolled hypertension despite of medication (> 150/100
             mmHg), New York Heart Association (NYHA) class III or IV heart disease,unstable angina
             or myocardial infarction within the past 1 year prior the study entry, history of
             significant ventricular arrhythmia requiring treatment)

          -  Inability to consciously sign the consent form due to physical or psychological
             disabilities
Clinical trial NCT02269319 (phase 2, status: completed)
Conditions: bacterial infections
ICD codes: A49.9, A04.9, A04.8, A49.8
Drugs: mrx-i, linezolid
SMILES: FC1=C(N2CCC(=O)C=C2)C(F)=C(F)C(=C1)N1C[C@H](CNC2=NOC=C2)OC1=O, CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with systemic signs of infection diagnosed with acute bacterial skin and skin
             structure infection (ABSSSI)

          -  Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections

        Exclusion Criteria:

          -  Uncomplicated skin infections

          -  Severe sepsis or septic shock

          -  ABSSSI solely due to gram-negative pathogens

          -  Prior systemic antibiotics within 96 hours of randomization
Clinical trial NCT02269943 (phase 2, status: completed)
Conditions: nasopharyngeal neoplasms
ICD codes: A36.1, B87.3
Drugs: cc-486
SMILES: NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Age = or > 18 years Histological or cytological diagnosis of undifferentiated or
             poorly differentiated nasopharyngeal carcinoma that is locally advanced or metastatic.

          -  Disease progression either clinically or radiographically after 1-2 previous regimens.

          -  Patient has received a platinum containing regimen. Eastern Cooperative Oncology Group
             (ECOG) performance status 0-2. Radiographically-documented measureable disease.

          -  Adequate organ and bone marrow functions.

          -  Willingness to follow pregnancy precautions.

        Exclusion Criteria:

          -  History of, or current brain metastasis. Any other malignancy within 5 years prior to
             randomization with the exception of adequately treated in situ carcinoma of the
             cervix, uteri, or non-melanomatous skin cancer (all treatment of which should have
             been completed 6 months prior to enrollment), in situ squamous cell carcinoma of the
             breast, or incidental prostate cancer.

          -  Previous treatment with azacitidine (any formulation), decitabine, any other
             hypomethylating agent.

          -  History of gastrointestinal disorder or defect. Impaired ability to swallow oral
             medication. Persistent diarrhea or malabsorption.

          -  Active cardiac disease and human immunodeficiency virus (HIV) infection

          -  Active bleeding; pathological condition that carries a high risk of bleeding; risk of
             pseudoaneurysm of the internal carotid artery and carotid blowout syndrome.

          -  Major surgery within 14 days prior to starting Investigational Product or has not
             recovered from major side effects.

          -  Another investigational therapy within 28 days or 5 half lives of
             randomization/enrollment, whichever is shorter.

          -  Patient has not recovered from the acute toxic effects of prior anticancer therapy,
             radiation, or major surgery/significant trauma.

          -  Radiotherapy < or = 4 weeks or limited field radiation for palliation < or = 2 weeks
             prior to starting with the investigational product.

          -  Pregnancy/Breast feeding

          -  Any condition that places the patient at unacceptable risk if he/she were to
             participate in the study or that confounds the ability to interpret data from the
             study.
Clinical trial NCT02270983 (phase 2, status: completed)
Conditions: opioid-induced constipation
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: linaclotide 145 micrograms, linaclotide 290 micrograms, placebo
SMILES: [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O, [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has chronic non-cancer pain that has been present for a minimum of 3 months

          -  Patient has been receiving a stable oral dose of a full-opioid agonist for at least 4
             days per week during the 8 consecutive weeks

          -  Patient meets protocol criteria for Opioid-Induced Constipation (OIC): < 3 spontaneous
             bowel movements (SBMs) per week and reports one of the following symptoms for at least
             4 weeks:

               1. Straining during > 25% of BMs

               2. Lumpy or hard stools during > 25% of BMs

               3. Sensation of incomplete evacuation during > 25% of BMs

          -  Patient meets the colonoscopy requirements defined by the American Gastroenterological
             Association guidelines

          -  Patient has successfully completed protocol procedures (with no clinically significant
             findings)

          -  Patient is compliant with Interactive Voice Response System (IVRS) for daily diary
             reporting

          -  Patient has a total of < 6 SBMs in IVRS during the 14 days before and up to the time
             of Randomization

          -  Patient has adequate relief and well-controlled pain with current dose of opioid

        Exclusion Criteria:

          -  Patient has been using opioids for abdominal pain

          -  Patient has symptoms of or been diagnosed with chronic constipation or chronic
             idiopathic constipation prior to initiation of opioid treatment

          -  Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS) prior to
             initiation of opioid treatment

          -  Patient has a history of loose or watery stools for > 25% of BMs during the 3 months
             before the Screening in the absence of laxatives, suppositories, or enemas

          -  Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease
             or condition that can affect GI motility

          -  Patient has any protocol-excluded or clinically significant medical or surgical
             history that would limit the patient's ability to complete or participate in this
             clinical trial or could confound the study assessments